Exclusive Student Offer

Prime for Young Adults

Get a 6-month trial with premium college perks & fast delivery.

Start Free Trial
Listen Anywhere

Audible Standard Trial

Get 30 days of audiobooks free. Cancel anytime, keep your books.

Claim Free Books

Analysts classified the Biontech paper in the past month.

The Biontech (ADRS) share was analyzed by 2 experts in January 2025.

1 expert recommends the share to buy, 1 expert recommends keeping the Biontech (ADRS) share.

The average price target of the analysts is $ 128.50. This means an expected increase of $ 4.80 to the current NAS course of Biontech (ADRS) share of USD 123.70.

The 6-month rating trend is on Buy.

AnalystPrice targetDistance targetDate
JP Morgan Chase & Co.USD 120.00-2.9901/27/2025
Goldman Sachs Group Inc.USD 137.0010.7501/15/2025

Editor finance.net

Selected leverage products on Biontech (ADRS)

With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Biontech (ADRS)

Advertising

ttn-28

Get Audible 30-Day Free Trial

As an Amazon Associate, we earn from qualifying purchases.